MAIA Biotechnology’s Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients

All NewsJune 5, 2025

MAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent